Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer

SET nuclear proto-oncogene (SET) deregulation is a novel molecular target in metastatic colorectal cancer (CRC). However, its role in CRC progression and its potential clinical impact in early-stage CRC patients remain unknown. Here, we studied the biological effects of SET on migration using wound-healing and transwell assays, and anchorage-independent cell growth using soft agar colony formation assays after ectopic SET modulation. SET was analyzed by immuno-staining in 231 early-stage CRC patients, and miR-199b expression was quantified by real-time PCR in a set of CRC patients. Interestingly, SET enhances cell migration, markedly affects the colony-forming ability, promotes epithelial to mesenchymal transition, and induces the expression of the MYC proto-oncogene (c-MYC) in CRC cells. SET overexpression was detected in 15.4% of cases and was associated with worse Eastern Cooperative Oncology Group (ECOG) status (p = 0.021) and relapse in stage-II CRC patients (p = 0.008). Moreover, SET overexpression predicted shorter overall survival (p < 0.001) and time to metastasis (p < 0.001), and its prognostic value was particularly evident in elderly patients. MiR-199b downregulation was identified as a molecular mechanism to deregulate SET in patients with localized disease. In conclusion, SET overexpression is a common alteration in early-stage CRC, playing an oncogenic role associated with progression and aggressiveness, and portends a poor outcome. Thus, SET emerges as a novel potential molecular target with clinical impact in early-stage in CRC.

[1]  H. Nagano,et al.  Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis , 2018, Molecular Cancer Research.

[2]  M. Vitek,et al.  OP449 inhibits breast cancer growth without adverse metabolic effects. , 2017, Endocrine-related cancer.

[3]  Kuen-Feng Chen,et al.  Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer , 2017, Expert opinion on therapeutic targets.

[4]  C. Shiau,et al.  Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential , 2016, Oncogene.

[5]  F. Rojo,et al.  Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer , 2016, Oncotarget.

[6]  F. Rojo,et al.  Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review , 2016, Current medical research and opinion.

[7]  M. Sweet,et al.  Using the MCoTI-II Cyclotide Scaffold To Design a Stable Cyclic Peptide Antagonist of SET, a Protein Overexpressed in Human Cancer. , 2016, Biochemistry.

[8]  Kuen-Feng Chen,et al.  SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A , 2015, Oncotarget.

[9]  A. Zentella,et al.  Protein phosphatase 2A is essential to maintain active Wnt signaling and its Aβ tumor suppressor subunit is not expressed in colon cancer cells , 2015, Molecular carcinogenesis.

[10]  Hongsheng Wang,et al.  Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer , 2015, Oncotarget.

[11]  F. Rojo,et al.  Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer , 2014, Clinical Cancer Research.

[12]  F. Rojo,et al.  Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. , 2014, Biochimica et biophysica acta.

[13]  F. Rojo,et al.  Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer , 2014, British Journal of Cancer.

[14]  Colin J. Daniel,et al.  Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer , 2014, Molecular Cancer Research.

[15]  Lei Dong,et al.  Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer , 2014, Oncology letters.

[16]  Sandra Zazo,et al.  PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential , 2014, Molecular Cancer Therapeutics.

[17]  R. Sears,et al.  Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia , 2014, Clinical Cancer Research.

[18]  R. Chaguturu,et al.  Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment , 2013, Cancer biology & therapy.

[19]  M. Juneja,et al.  Anti-metastatic treatment in colorectal cancer: targeting signaling pathways. , 2012, Current pharmaceutical design.

[20]  E. Tajara,et al.  SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. , 2012, Oral oncology.

[21]  M. Odero,et al.  Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia , 2012, Haematologica.

[22]  G. Grosveld,et al.  SET Oncogene is Upregulated in Pediatric Acute Lymphoblastic Leukemia , 2012 .

[23]  X. Yao,et al.  I2 PP2A regulates p53 and Akt correlatively and leads the neurons to abort apoptosis , 2012, Neurobiology of Aging.

[24]  M. Vitek,et al.  SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. , 2011, Blood.

[25]  Ji-Young Kim,et al.  Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity , 2011, Nucleic acids research.

[26]  D. Wink,et al.  Targeting SET/I2PP2A Oncoprotein Functions as a Multi-pathway Strategy for Cancer Therapy , 2010, Oncogene.

[27]  G. Colucci,et al.  Adjuvant colon cancer chemotherapy: where we are and where we'll go. , 2010, Cancer treatment reviews.

[28]  K. Kang,et al.  Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. , 2010, Cancer letters.

[29]  J. Marshall,et al.  Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents , 2010, Gastrointestinal cancer research : GCR.

[30]  Tzu-Hao Wang,et al.  Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. , 2010, Cancer letters.

[31]  W. Hahn,et al.  Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.

[32]  M. Mumby.  PP2A: Unveiling a Reluctant Tumor Suppressor , 2007, Cell.

[33]  P. Hordijk,et al.  Rac1‐induced cell migration requires membrane recruitment of the nuclear oncogene SET , 2007, The EMBO journal.

[34]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Guido Marcucci,et al.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.

[36]  J. Lieberman,et al.  Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor , 2003, Cell.

[37]  O. Bachs,et al.  The SET Protein Regulates G2/M Transition by Modulating Cyclin B-Cyclin-dependent Kinase 1 Activity* , 2003, The Journal of Biological Chemistry.

[38]  M. Szyf,et al.  The Oncoprotein Set/TAF-1β, an Inhibitor of Histone Acetyltransferase, Inhibits Active Demethylation of DNA, Integrating DNA Methylation and Transcriptional Silencing* , 2002, The Journal of Biological Chemistry.

[39]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[40]  P. McNamara,et al.  Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein , 2001, Cell.

[41]  J. Woodgett,et al.  Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. , 1999, The Biochemical journal.

[42]  Z. Damuni,et al.  The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A (*) , 1996, The Journal of Biological Chemistry.

[43]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[44]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[45]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.